Solanezumab in‐depth outcomes

Authors :: Roger Clarnette
Ivonne Z. Jimenez-Velazquez
Ghulam M. Surti
Suman Jayadev
Anne M. Fagan
Clifford R. Jack
Peter J. Snyder
Christopher H. van Dyck
Erik D. Roberson
Guoqiao Wang
Mario Masellis
David B. Clifford
Chengjie Xiong
Randall J. Bateman
Jérémie Pariente
Tammie L.S. Benzinger
Ging-Yuek Robin Hsiung
Serge Gauthier
Rachelle S. Doody
Paul Delmar
Didier Hannequin
Doug R. Galasko
Sarah B. Berman
Florence Pasquier
Robert A. Koeppe
James J. Lah
Carlos Cruchaga
Paulo Fontoura
Alison Goate
Eric McDade
Raquel Sánchez-Valle
David Wallon
Dian‐Tu Study Team
Catherine J. Mummery
Colin L. Masters
Jared R. Brosch
Maïté Formaglio
B. Joy Snider
Susan Mills
Monika Baudler
Lawrence S. Honig
Bruno Dubois
John C. Morris
Kelley Coalier
Brian A. Gordon
Stephen Salloway
Andrew J. Aschenbrenner
Jason Hassenstab
Anna Santacruz
William S. Brooks
Geoffrey A. Kerchner
Martin R. Farlow
Source :: Alzheimer's & Dementia. 16
Publication Year :: 2020
Publisher :: Wiley, 2020.

Subjects :: Oncology
medicine.medical_specialty
Epidemiology
business.industry
Health Policy
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Developmental Neuroscience
Internal medicine
medicine
Neurology (clinical)
Solanezumab
Geriatrics and Gerontology
business
Gantenerumab
medicine.drug

Full Text Access

Tools